Peter R. Kowey

About

• 2009–Present: Professor, Lankenau Institute for Medical Research
• 2008–Present: William Wikoff Smith Chair in Cardiovascular Research
• 2000–Present: President, The Heart Center of Lankenau, Bryn Mawr, and Paoli Hospitals
• 1999–2016: Chief, Division of Cardiovascular Diseases, Main Line Health
• 1990–Present: Professor of Medicine and Clinical Pharmacology, Jefferson Medical College, Thomas Jefferson University

Publications

Books

• Management of Cardiac Arrhythmias. Yan G-X, Kowey PR, Antzelevitch C, eds. Springer; 2020.
• Cardiac Arrhythmias, Pacing and Sudden Death. Kowey PR, Piccini JC, Naccarelli G, Reiffel JA, eds. Springer; 2017.

Journal articles

• Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design. Jain SS, Mahaffey KW, … Kowey PR, et al. Am Heart J. 2024. https://doi.org/10.1016/j.ahj.2024.08.011.
• Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation. Piccini JP, Ahlsson A, … Kowey PR, et al. JACC Clin Electrophysiol. 2024 May;10(5):930-940. doi: 10.1016/j.jacep.2024.01.020
• Comparing left bundle branch area versus right ventricular septal pacing in high-degree conduction disease after TAVR: Randomized trial study protocol Left Bundle BRAVE: Study protocol. Liskov S, Olleik F, Jarrett H, Abramson S, Kowey P, … Keramati AR. CJC Open, https://doi.org/10.1016/j.cjco.2024.05.006.
• Orally Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm: INSTANT Phase 2 Trial. Ruskin JN, Camm AJ, … Kowey PR, et al. JACC Clin Electrophysiol. 2024 Mar 26:S2405-500X(24)00164-6. doi: 10.1016/j.jacep.2024.02.021
• Antiarrhythmic Drug Therapy: Where Do We Go From Here? Kowey PR, Naccarelli GV. Circulation. 2024 Mar 12;149(11):801-803.
• Should Patients with Subclinical Atrial Fibrillation Receive Anticoagulation? Reiffel JA, Kowey PR, Naccarelli GV. Am J Med. 2024 Jan 26:S0002-9343(24)00042-1. doi: 10.1016/j.amjmed.2024.01.009
• A Multicenter, Phase 2, Randomized, Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients with Symptomatic Atrial Fibrillation (ReVeRA-201). Camm AJ, Piccini JP, … Kowey PR, et al. Circ Arrhythm Electrophysiol. 2023 Dec;16(12):639-650.
• How Antiarrhythmic Drugs Are Being Used in Patients With Heart Failure: Results of a Global Survey of Cardiologists. Spears J, Liskov S, … Kowey PR. Am J Cardiol. 2023 Sep 6;206:60-62.
• Dronedarone Versus Sotalol in Antiarrhythmic Drug-Naive Veterans With Atrial Fibrillation. Pundi K, Fan J, … Kowey P, et al. Circ Arrhythm Electrophysiol. 2023 Aug;16(8):456-467.
• Real-world utilization of the pill-in-the-pocket method for terminating episodes of atrial fibrillation: data from the multinational Antiarrhythmic Interventions for Managing Atrial Fibrillation (AIM-AF) survey. Reiffel JA, Blomström-Lundqvist C, … Kowey PR, et al. Europace. 2023 Jun 2;25(6).
• Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial. Stambler BS, Camm AJ, …, Kowey PR, et al. Lancet. 2023 Jun 15:S0140-6736(23)00776-6. doi: 10.1016/S0140-6736(23)00776-6
• A Review of the Cardiovascular Safety of Prucalopride in Patients With Chronic Idiopathic Constipation. Tack J, Derakhchan K, … Kowey PR, et al. Am J Gastroenterol. 2023 Jun 1;118(6):955-960. doi: 10.14309/ajg.0000000000002249
• Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta-analysis. Singh JP, Blomström-Lundqvist C, … Kowey PR. Clin Cardiol. 2023 Jun;46(6):589-597.
• A Review of the Cardiovascular Safety of Prucalopride in Patients with Chronic Idiopathic Constipation. Tack J, Derakhchan K, … Kowey PR, et al. Am J Gastroenterol. 2023 Mar 16. doi: 10.14309/ajg.0000000000002249
Initial Findings From the National Cardiovascular Data Registry of Atrial Fibrillation Ablation Procedures. Hsu JC, Darden D, … Kowey PR. J Am Coll Cardiol. 2023 Mar 7;81(9):867-878.
• Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT. Olshansky B, Bhatt DL, … Kowey PR, et al. J Am Heart Assoc. 2023 Feb 21:e026756. doi: 10.1161/JAHA.121.02675
• Perspective on Antiarrhythmic Drug Combinations. Reiffel JA, Robinson VM, Kowey PR. Am J Cardiol. 2023 Feb 11;192:116-123. doi: 10.1016/j.amjcard.2023.01.035
• Marked QTc Reduction Immediately Following Direct Current Cardioversion of Atrial Fibrillation: Clinical Implications and Mechanisms. Omondi A, Sirinvaravong N, Spears J, Sauerwein S, Taoutel R, Liskov S, …. Kowey PR, Yan GX. JACC Clin Electrophysiol. 2022 Nov 16:S2405-500X(22)00948-3. doi: 10.1016/j.jacep.2022.10.031
• Amiodarone for the prevention of shocks and death in patients with implantable cardioverter-defibrillators: Hero or villain? Spears J, Kowey P. Heart Rhythm. 2023. https://doi.org/10.1016/j.hrthm.2023.01.006
• The development of a mobile app-focused deduplication strategy for the Apple Heart Study that informs recommendations for future digital trials. Garcia A, Lee J, … Kowey P, et al. Stat (Int Stat Inst). 2022 Dec;11(1):e470. doi: 10.1002/sta4.470
• Residual Stroke Risk Despite Oral Anticoagulation in Patients with Atrial Fibrillation. Carlisle MA, Shrader P, … Kowey PR, … Ezekowitz, MD, et al. Heart Rhythm O2, 2022 Sep 28;3(6Part A):621-628.
• I'm Sorry, Ms Jones, But We Cannot Make You Feel Better Today. Circulation. Liskov S, Belardinelli L, Kowey P. 2022 Aug 30;146(9):655-656. doi: 10.1161/CIRCULATIONAHA.122.060488
• The development of a mobile app-focused deduplication strategy for the Apple Heart Study that informs recommendations for future digital trials. Garcia A, Lee J, … Kowey P, et al. Stat, 11( 1), e470. https://doi.org/10.1002/sta4.470
• Lessons learned in the Apple Heart Study and implications for the data management of future digital clinical trials. Garcia A, Balasubramanian V, … Kowey P, et al. J. Biopharm. Stat. 2022 12 Jun. doi: 10.1080/10543406.2022.2080698
• Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies. Handelsman Y, Bunch TJ, … Thind M, … Kowey P. J. Diabetes Complications. 2022 Jul;36(7):108227.
• Increased susceptibility to ventricular arrhythmia at low-normal and moderately-low levels of extracellular potassium in Catecholaminergic Polymorphic Ventricular Tachycardia. Robinson VM, Di Diego JM, … Kowey P, Antzelevitch C, Venetucci L. Heart Rhythm. 2022 Aug;19(8):1389-1391.
• AIM‐AF: A Physician Survey in the United States and Europe. Camm AJ, Blomstrom-Lundqvist CB, … Kowey PR, et al. J. Am. Heart Assoc. Mar 4 2022;0:e023838
• Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm. Crijns HJGM, Elvan A, … Kowey PR, et al. Circ Arrhythm Electrophysiol. 2022 Feb 24:CIRCEP121010204. doi: 10.1161/CIRCEP.121.010204
• Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies. Thind M, McKindley DS, … Kowey PR. Clin Cardiol. 2022 Jan 15. doi: 10.1002/clc.23768.
• Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: post hoc analyses of the EURIDIS-ADONIS trials. Thind M, Zareba W, … Kowey P. Clinical Cardiology. 2022; 1-9.
• Use of the HAVOC Score to Identify Patients at Highest Risk of Developing Atrial Fibrillation. Elkind MSV, Wachter R, … Kowey PR, et al. Cardiology. 2021;146(5):633-640.
• Design and Rationale of a Phase 2 Study of NeurOtoxin (Botulinum Toxin Type A) for the PreVention of Post-Operative Atrial Fibrillation - The NOVA Study. Piccini JP, Ahlsson A, … Kowey PR, et al. Am Heart J. 2022 Mar;245:51-59.
• Arrhythmias Other Than Atrial Fibrillation in Those With an Irregular Pulse Detected With a Smartwatch: Findings From the Apple Heart Study. Perino AC, Gummidipundi SE, … Kowey P, et al. Circ Arrhythm Electrophysiol. 2021 Oct;14(10):e010063.
• Intracellular Uptake of Agents That Block the hERG Channel Can Confound Assessment of QT Prolongation and Arrhythmic Risk. Burashnikov A, Barajas-Martinez H, Cox R, … Kowey P, Antzelevitch C. Heart Rhythm. 2021 Dec;18(12):2177-2186.
• Reexamination of the Embolic Stroke of Undetermined Source Concept. Albers GW, Bernstein R, … Kowey P. Stroke. 2021 Jul 1:STROKEAHA121035208. doi: 10.1161/STROKEAHA.121.035208
• Cherry-picking Atrial Fibrillation Ablation Responders: Can Antiarrhythmic Drugs Help? Kreidieh B, Thind M, Kowey PR. Heart Rhythm. 2021 Sep;18(9):1480-1481.
• Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). Jackson LR 2nd, Schrader P, … Kowey PR, et al. Am J Cardiovasc Drugs.2021 Sep;21(5):553-561.
• Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial. Turakhia M, Sundaram V, … Kowey PR, et al. Am Heart J. 2021 Jul;237:68-78.
• Relation of Antecedent Symptoms to the Likelihood of Detecting Subclinical Atrial Fibrillation with Inserted Cardiac Monitors. Reiffel JA, Verma A, Kowey PR, et al. Am J Cardiol. 2021 Jan 23:S0002-9149(21)00041-2.
• Medicine on Twitter: Boon or Bane? Kowey PR, Robinson VM, Thind M. Circ Arrhythm Electrophysiol. 2021 Jan;14(1):e009434.
• Bretylium, a Class III Antiarrhythmic, Returns to the Market. Thind M, Sullivan RM, Williams RN, Kowey PR. Am J Cardiol. 2020 Jul 28:S0002-9149(20)30788-8.
• Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients with Atrial Fibrillation (from ORBIT AF). Madhavan M, Holmes DN, Piccini JP, … Kowey PR, et al. Am J Cardiol. 2020 Jul 12:S0002-9149(20)30674-3.
• Patterns of oral anticoagulation use with cardioversion in clinical practice. Geurink K, Holmes D, Ezekowitz MD, Pieper K, Fonarow G, Kowey PR, et al. Heart. 2020 Jun 26:heartjnl-2019-316315.
• Outcomes of Cardiac Catheterization in Patients with Atrial Fibrillation on Anticoagulation in Contemporary in Practice. Sherwood MW, Piccini JP, Homes DN, … Kowey PR, et al. Circ Cardiovasc Interv 2020 May;13(5):e008274.
• Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from ORBIT-AF II. Jackson LR 2nd, Kim S, Blanco R, … Kowey PR, et al. Am Heart J. 2020 Apr 28;226:85-93.
• Shared Decision Making in Atrial Fibrillation: Patient-Reported Involvement in Treatment Decisions. Ali-Ahmed F, Pieper K, North R, Allen LA, Chan PS, Ezekowitz MD, … Kowey PR, et al. Eur Heart J Qual Care Clin Outcomes. 2020 May 11:qcaa040. doi: 10.1093/ehjqcco/qcaa040.
• The Relentless Pursuit of New Drugs to Treat Cardiac Arrhythmias. Kowey PR, Robinson VM. Circulation. 2020 May 12;141(19):1507-09.
• The Role of the Food and Drug Administration in Drug Development: On the Subject of Proarrhythmia Risk. Thind M, Kowey PR. J Innov Card Rhythm Manag. 2020 Jan 15;11(1):3958-67.
• Factors Associated with Large Improvements in Health-Related Quality of Life in Patients with Atrial Fibrillation: Results from ORBIT-AF. Steinberg BA, Holmes DN, Pieper K, Allen LA, Chan PS, Ezekowitz MD, … Kowey PR, et al. Circ Arrhythm Electrophysiol. 2020 Apr 16. doi: 10.1161/CIRCEP.119.007775.
• Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. Dalgaard F, North R, Pieper K, Fonarow GC, Kowey PR, … Ezekowitz M, et al. Am Heart J. 2020 Jan 7;223:65-71.
• Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: a post hoc analysis of the EURIDIS and ADONIS trials. Thind M, Crijns HJ, Naccarelli GV, … Kowey PR, et al. J Cardiovasc Electrophysiol. 2020 Feb 21.
• General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy. Li Z, Mirams GR, Yoshinaga T … Kowey, PR, et al. Clin Pharmacol Ther. 2020 Jan;107(1):102-11.
• Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Inohara T, Holmes DN, Pieper K, … Ezekowitz MD, Kowey PR, et al. Heart. 2020 Jan 7. pii: heartjnl-2019-315792.
• Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study. Vamos M, Calkins H, Kowey PR, et al. Clin Cardiol. 2019 Dec 24.
• Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study. Reiffel JA, Verma A, Kowey PR, et al. Am Heart J. 2020 Jan;219:128-36.
• Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. Freeman JV, Shrader P, Pieper KS, … Kowey PR, et al. Circ Arrhythm Electrophysiol. 2019 Dec;12(12):e007612.
• Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. Pokorney SD, Holmes DN, Shrader P, … Kowey PR, et al. Am Heart J. 2019 Oct 23;220:145-54.
• The Evolution of the One-Armed Bandit. Kowey PR, Robinson VM. J Am Coll Cardiol. 2019 Nov 12;74(19):2376-8.
• Changes in Management Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor (from the REVEAL AF Study). Verma A, Wachter R, Kowey PR, et al. Am J Cardiol. 2019 Jun 24.
• Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. Pokorney SD, Holmes DN, Thomas L, Fonarow GC, Kowey PR, et al. JAMA Cardiol. 2019 Jul 3.
• Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. Inohara T, Shrader P, Pieper K, Kowey PR, … et al. Am Heart J. 2019 Apr 24;213:81-90.
• Strategies to Reduce Recurrent Shocks Due to Ventricular Arrhythmias in Patients with an Implanted Cardioverter-Defibrillator. Back SH, Kowey PR. Arrhythm Electrophysiol Rev. 2019 Mar;8(2):99-104.
• Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. Holmes DN, Piccini JP, Allen LA, Kowey PR, … et al. Circ Cardiovasc Qual Outcomes. 2019 May;12(5):e005358.
• Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT-AF Registry. Perino AC, Shrader P … Kowey PR, et al. J Am Heart Assoc. 2019 May 7;8(9):e011205.
• Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry). Vemulapalli S, Inohara T, Kim S … Ezekowitz M, Kowey PR, et al. The American Journal of Cardiology 2019 123(10):1628–36.
• Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. Madhavan M, Holmes DN, Piccini JP, … Kowey PR, et al. Am Heart J. 2019 Jan 30;211:77-89.
• Cardioversion of obese patients: What is the weight of evidence? Kowey PR, Ahmad S.J Cardiovasc Electrophysiol. 2018 Dec 16. doi: 10.1111/jce.13814.
• Pharmacological Therapy for Ventricular Arrhythmias: A State-of-the Art Review. Chia KKM, Kanagaratnam L, Hellestrand K, Kowey P, Whalley D. Heart Lung Circ. 2018 Oct 15. Review.
• Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study. Turakhia MP, Desai M, Hedlin H, Rajmane A, … Kowey P, et al. Am Heart J. 2018 Sep 8.
• Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF. Washam JB, Holmes DN, Thomas, LF … Kowey PR, et al. JAHA. 2018;7(19).
• B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. Inohara T, Kim S, Pieper K, Ezekowitz MD, Kowey PR, et al. Heart. 2018. Sep 18.
• Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). Thind M, Holmes DN, Badri M, Kowey PR, … et al. Am J Cardiol. 2018 Aug 20.
• Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2‐VASc Scores: Findings From the ORBIT‐AF I and II Registries. Jackson LR, Kim S, Fonarow GC, … Kowey PR, et al. 16 Aug 2018 Journal of the American Heart Association.7:e008764.
• Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Jackson LR 2nd, Kim S, Shrader P, Blanco R, Thomas L, Ezekowitz MD, Ansell J, Fonarow GC, Gersh BJ, Go AS, Kowey PR, et al. J Thromb Thrombolysis. 2018 Jul 26, pp1-5.
• A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation. Camm JA, Dorian P, Hohnloser SH, Kowey PR, et al. Eur Heart J Cardiovasc Pharmacother. 2018 Jul 23;11(14):1401-10.
• The Second Annual Think Tank on Prevention of Sudden Cardiac Death in the Young: Developing a rational, reliable, and sustainable national health care resource. A report from the Cardiac Safety Research Consortium. Aziz PF, Berger S, Kowey P, et al. Am Heart J. 2018 May 23;202:104-108. Review.
• Building Castles in the Sky: Catheter Ablation in Patients With Atrial Fibrillation and Chronic Heart Failure. Packer M, Kowey PR. Circulation. 2018 May 30.
• Drug-induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and Pharmacy.Turner JR, Rodriguez I, Mantovani E, Gintant G, Kowey PR, et al. Cardiac Safety Research Consortium. J Clin Pharmacol. Apr 19, 2018. doi: 10.1002/jcph.1129. Review.
• Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry. Fudim M, Liu PR, Shrader P, ... Kowey PR, et al. J Am Heart Assoc. Apr 13, 2018;7(8). doi: 10.1161/JAHA.117.007987.
• Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation. White WB, Kowey P, Diva U, Sostek M, Tummala R. J Cardiovasc Pharmacol Ther. 2018 Jan 1:1074248418760239. doi: 10.1177/1074248418760239.
• Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). Steinberg BA, Shrader P, Pieper K, … Kowey PR, et al. J Am Heart Assoc. 2018 Feb 16;7(4).
• Assessing intracardiac thrombus prior to cardioversion: A story yet to be told. Anouti K, Kowey PR. J Cardiovasc Electrophysiol. 2018 Feb 13. doi: 10.1111/jce.13462.
• Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF. Thomas KL, Jackson LR 2nd, Shrader P, Ansell J, Fonarow GC, Gersh B, Kowey PR, et al. J Am Heart Assoc. 2017 Dec 22;6(12). pii: e006475.
• International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Steinberg BA, Gao H, Kowey PR, et al. Am Heart J. 2017 Dec;194:132-140.
• Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation). Barnett AS, Kim S, Fonarow GC, ... Kowey PR, et al. Circ Arrhythm Electrophysiol. 2017 Nov;10(11). doi:10.1161/CIRCEP.117.005051.
• Association of Atrial Fibrillation Clinical Phenotypes with Treatment Patterns and Outcomes: A Multicenter Registry Study. Inohara T, Shrader P, Pieper K, … Kowey PR, et al. JAMA Cardiol. 2017 Nov 12. doi: 10.1001/jamacardio.2017.4665.  
• Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. Echouffo-Tcheugui JB, Shrader P, Thomas L, Gersh BJ, Kowey PR, et al. J Am Coll Cardiol. 2017 Sep 12;70(11):1325-1335.
• Disease understanding in patients newly diagnosed with atrial fibrillation. Kaufman BG, Kim S, Pieper K, … Kowey PR, et al. Heart. 2017 Aug 8.
• Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study. Reiffel JA, Verma A, Kowey PR, Halperin JL, Gersh BJ, Wachter R, Pouliot E, Ziegler PD; REVEAL AF Investigators. JAMA Cardiol. 2017 Aug 26.
• Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Melloni C, Shrader P, Carver J, ... Kowey PR; ORBIT-AF Steering Committee. Eur Heart J Qual Care Clin Outcomes. 2017 Jul 1;3(3):192-197.
• Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Steinberg BA, Shrader P, Thomas L, ... Kowey PR, et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Am Heart J. 2017 Jul;189:40-47.
• Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the ORBIT-AF II. Steinberg BA, Simon DN, Thomas L, Kowey PR, et al. ORBIT-AF Investigators and Patients.. Am J Cardiol. 2017 May 15;119(10):1590-1595.
• Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. Freedman B, Camm J, Calkins H, Kowey PR, et al. Circulation. 2017 May 9;135(19):1851-1867.
• Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium. Piccini JP, Clark RL, Kowey PR, et al. Am Heart J. 2017 May;187:156-169.
• Cardioversion and subsequent quality of life and natural history of atrial fibrillation. Pokorney SD, Kim S, Thomas L, Fonarow GC, Kowey PR, et al. Am Heart J. 2017 Mar;185:59-66.
• Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial. Robinson VM, Bharucha DB, Mahaffey KW, Dorian P, Kowey PR; SHIELD-2 Investigators. Am Heart J. 2017 Mar;185:43-51.
• Acquired Long QT Syndrome in Hospitalized Patients. Yu H, Zhang L, Liu J, Liu Y, Kowey PR,,et al. Heart Rhythm. 2017 Mar 16.
• The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review. Hess PL, Healey JS, Granger CB, … Kowey PR, et al. JAMA Cardiol. 2017 Mar 1;2(3):324-331.
• The burden of proof: The current state of atrial fibrillation prevention and treatment trials. Zakeri R, Van Wagoner DR, Calkins H, ... Kowey PR, et al. Heart Rhythm. 2017 Feb 2.
• Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF Study. Conti S, Reiffel JA, Gersh BJ, Kowey PR, et al. J Atr Fibrillation. 2017 Feb 28;9(5):1551.
• Regional Lack of Consistency in the Management of Atrial Fibrillation (from the RECORD-AF Trial). Darrat YH, Shah J, Elayi CS, ... Kowey PR, et al. Am J Cardiol. 2017 Jan 1;119(1):47-51.
• QT interval shortening with isavuconazole: In vitro and In vivo effects on cardiac repolarization. Keirns J, Desai A, Kowalski D, … Kowey PR, et al. Clin Pharmacol Ther. 2017 Jan 11.
• Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. Pandey A, Kim S, Moore C, ... Kowey PR, et al. JACC Heart Fail. 2017 Jan;5(1):44-52.
• Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. Steinberg BA, Shrader P, Thomas L, … Kowey PR, et al. J Am Coll Cardiol. 2016 Dec 20;68(24):2597-2604.
• Patient factors associated with quality of life in atrial fibrillation. Randolph TC, Simon DN, Thomas L, ... Kowey PR, et al. Am Heart J. 2016 Dec;182:135-143.
• Back to the basics. Hanley CM, Kowey PR. Heart Rhythm. 2016 Nov 30. pii: S1547-5271(16)31154-7.
• Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. Hess PL, Kim S, Fonarow GC, … Kowey PR, et al. Am J Med. 2016 Nov 22. pii: S0002-9343(16)31195-0.
• How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from ORBIT-AF. Steinberg BA, Shrader P, Kim S, ... Kowey PR, et al. Am Heart J. 2016 Nov;181:145-152.
• Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Pokorney SD, Shrader P, Thomas L, Fonarow GC, Kowey PR, et al. 2016 Oct 11;134(15):1122-1124.
• Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. Piccini JP, Pritchett EL, Davison BA, ... Kowey PR, et al Heart Rhythm. 2016 Apr 19.
• Antiarrhythmic Drug Therapy for Atrial Fibrillation. Sardar MR, Saeed W, Kowey PR. Heart Fail Clin. 2016 Apr;12(2):205-21.
• Darned If You Do…Darned If You Don't. Hanley CM, Kowey PR. J Cardiovasc Electrophysiol. 2016 Apr 24. [Epub ahead of print]
• Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report. Albers GW, Bernstein RA, Brachmann ... Kowey PR. J Am Heart Assoc. 2016 Mar 15;4(3):e002944.
• Status of Antiarrhythmic Drug Development for Atrial Fibrillation: New Drugs and New Molecular Mechanisms. Hanley CM, Robinson VM, Kowey PR. Circ Arrhythm Electrophysiol. 2016 Mar;9(3):e002479.
• Smoothing the Bumpy Road to Antiarrhythmic Drug Development. Robinson VM, Kowey PR. Circulation. 2015 Dec 8;132(23):2195-7.
• Practical Considerations for the Nonvitamin K Antagonist Oral Anticoagulants. Trikha R, Kowey PR. Cardiology. 2016 Sep 6;136(2):115-124.
• Update on atrial fibrillation. Khaji A, Kowey PR. Trends Cardiovasc Med. 2016 Jun 22. pii: S1050-1738(16)30084-6.
• Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men: Two-Year Results From the ORBIT-AF Registry. Piccini JP, Simon DN, Steinberg BA, … Kowey PR, et al. JAMA Cardiol. 2016 Jun 1;1(3):282-291. doi: 10.1001/jamacardio.2016.0529.
• The Cardiac Safety Research Consortium enters its second decade: An invitation to participate. Turner JR, Kowey PR, et al. Am Heart J. 2016 Jul;177:96-101. doi: 10.1016/j.ahj.2016.04.009.
• Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. Golwala H, Jackson LR 2nd, Simon DN, ... Kowey PR, et al. Outcomes Registry for Better Informed Treatment for Atrial Fibrillation (ORBIT-AF) Registry. Am Heart J. 2016 Apr;174:29-36. Epub 2015 Dec 30.
• Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Lopes RD, Rao M, Simon DN, T, ... Kowey P, et al. Am J Med. 2016 Jan 18.
• Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry. Jackson LR 2nd, Kim SH, Piccini JP Sr, ... Kowey PR, et al. Clin Cardiol. 2016 Feb;39(2):119-25. Epub 2015 Dec 31.
• Observing the Obvious. Kowey PR, Robinson VM. J Am Coll Cardiol. 2015 Sep 1;66(9):1008-10.